Logo image of ARDX

ARDELYX INC (ARDX) Stock Fundamental Analysis

USA - NASDAQ:ARDX - US0396971071 - Common Stock

5.2581 USD
+0.16 (+3.1%)
Last: 10/21/2025, 12:50:54 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ARDX. ARDX was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of ARDX have multiple concerns. ARDX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ARDX had negative earnings in the past year.
In the past year ARDX has reported a negative cash flow from operations.
In the past 5 years ARDX always reported negative net income.
ARDX had a negative operating cash flow in each of the past 5 years.
ARDX Yearly Net Income VS EBIT VS OCF VS FCFARDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ARDX's Return On Assets of -12.08% is amongst the best of the industry. ARDX outperforms 82.96% of its industry peers.
ARDX has a better Return On Equity (-40.41%) than 71.72% of its industry peers.
Industry RankSector Rank
ROA -12.08%
ROE -40.41%
ROIC N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ARDX Yearly ROA, ROE, ROICARDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ARDX has a better Gross Margin (84.80%) than 87.45% of its industry peers.
In the last couple of years the Gross Margin of ARDX has remained more or less at the same level.
ARDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
ARDX Yearly Profit, Operating, Gross MarginsARDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARDX has been increased compared to 1 year ago.
ARDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ARDX is higher compared to a year ago.
ARDX Yearly Shares OutstandingARDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ARDX Yearly Total Debt VS Total AssetsARDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ARDX has an Altman-Z score of 0.65. This is a bad value and indicates that ARDX is not financially healthy and even has some risk of bankruptcy.
ARDX has a Altman-Z score of 0.65. This is in the better half of the industry: ARDX outperforms 60.30% of its industry peers.
ARDX has a Debt/Equity ratio of 1.44. This is a high value indicating a heavy dependency on external financing.
ARDX has a worse Debt to Equity ratio (1.44) than 78.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.44
Debt/FCF N/A
Altman-Z 0.65
ROIC/WACCN/A
WACC9.66%
ARDX Yearly LT Debt VS Equity VS FCFARDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

ARDX has a Current Ratio of 4.30. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
ARDX has a Current ratio of 4.30. This is comparable to the rest of the industry: ARDX outperforms 48.31% of its industry peers.
A Quick Ratio of 4.03 indicates that ARDX has no problem at all paying its short term obligations.
The Quick ratio of ARDX (4.03) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.3
Quick Ratio 4.03
ARDX Yearly Current Assets VS Current LiabilitesARDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.70% over the past year.
Looking at the last year, ARDX shows a very strong growth in Revenue. The Revenue has grown by 83.88%.
Measured over the past years, ARDX shows a very strong growth in Revenue. The Revenue has been growing by 129.15% on average per year.
EPS 1Y (TTM)13.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)83.88%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%33.38%

3.2 Future

Based on estimates for the next years, ARDX will show a very strong growth in Earnings Per Share. The EPS will grow by 56.17% on average per year.
Based on estimates for the next years, ARDX will show a very strong growth in Revenue. The Revenue will grow by 21.57% on average per year.
EPS Next Y-105.51%
EPS Next 2Y54.58%
EPS Next 3Y75.69%
EPS Next 5Y56.17%
Revenue Next Year16.8%
Revenue Next 2Y21.83%
Revenue Next 3Y24.06%
Revenue Next 5Y21.57%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARDX Yearly Revenue VS EstimatesARDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
ARDX Yearly EPS VS EstimatesARDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ARDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 82.81, which means the current valuation is very expensive for ARDX.
Based on the Price/Forward Earnings ratio, ARDX is valued cheaply inside the industry as 87.83% of the companies are valued more expensively.
ARDX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.18.
Industry RankSector Rank
PE N/A
Fwd PE 82.81
ARDX Price Earnings VS Forward Price EarningsARDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDX Per share dataARDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

ARDX's earnings are expected to grow with 75.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y54.58%
EPS Next 3Y75.69%

More info and screens

0

5. Dividend

5.1 Amount

ARDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARDELYX INC

NASDAQ:ARDX (10/21/2025, 12:50:54 PM)

5.2581

+0.16 (+3.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners70.15%
Inst Owner Change-0.04%
Ins Owners2.17%
Ins Owner Change4.58%
Market Cap1.27B
Analysts87.78
Price Target11.41 (117%)
Short Float %8.42%
Short Ratio5.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.71%
Min EPS beat(2)-46.66%
Max EPS beat(2)41.25%
EPS beat(4)3
Avg EPS beat(4)103.02%
Min EPS beat(4)-46.66%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)72.17%
EPS beat(12)9
Avg EPS beat(12)548.58%
EPS beat(16)11
Avg EPS beat(16)410.93%
Revenue beat(2)1
Avg Revenue beat(2)5.14%
Min Revenue beat(2)-7.8%
Max Revenue beat(2)18.08%
Revenue beat(4)3
Avg Revenue beat(4)6.25%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)18.08%
Revenue beat(8)6
Avg Revenue beat(8)27.86%
Revenue beat(12)10
Avg Revenue beat(12)31.92%
Revenue beat(16)12
Avg Revenue beat(16)25.31%
PT rev (1m)0%
PT rev (3m)2.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.93%
EPS NY rev (1m)7.51%
EPS NY rev (3m)18.56%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)4.91%
Revenue NY rev (1m)-0.38%
Revenue NY rev (3m)5.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 82.81
P/S 3.28
P/FCF N/A
P/OCF N/A
P/B 9.08
P/tB 9.08
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)0.06
Fwd EY1.21%
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS1.6
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.08%
ROE -40.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.8%
FCFM N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score4
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 1.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 74.3%
Cap/Sales 0.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.3
Quick Ratio 4.03
Altman-Z 0.65
F-Score4
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)26.96%
Cap/Depr(5y)45.67%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-105.51%
EPS Next 2Y54.58%
EPS Next 3Y75.69%
EPS Next 5Y56.17%
Revenue 1Y (TTM)83.88%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%33.38%
Revenue Next Year16.8%
Revenue Next 2Y21.83%
Revenue Next 3Y24.06%
Revenue Next 5Y21.57%
EBIT growth 1Y31.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.62%
EBIT Next 3Y97.39%
EBIT Next 5Y63.27%
FCF growth 1Y21.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.14%
OCF growth 3YN/A
OCF growth 5YN/A